US › Healthcare

Tvardi Therapeutics, Inc. (TVRD)

US · Healthcare · Biotechnology

$1.01-5.61%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-6.5M

Profit YoY

-255.0%

EPS

$-0.69

EPS estimate

$-0.65

EPS came in at -0.69 against a street estimate of -0.65 — a miss of 6.2%.

Key statistics

Market cap

$13.9M

Forward P/E

0.0

P/B

2.08

Book value

$0.89

EPS (TTM)

$-2.84

52-week high

$7.23

52-week low

$0.93

50-day MA

$1.64

200-day MA

$2.99

Analyst view

Analysts rate Tvardi Therapeutics, Inc. a buy (7 buy, 1 hold, 1 sell out of 9) with an average price target of $9.25.

Shareholding

Insiders

24.36%

Institutions

17.34%

Largest institutional holders

Fund	Stake
Slate Path Capital LP	5.28%
Vanguard Capital Management, LLC	2.58%
American Financial Group Inc	1.68%
UBS Group AG	0.83%
Silvercrest Asset Management Group LLC	0.76%
BlackRock Inc	0.72%
Renaissance Technologies Corp	0.69%
Geode Capital Management, LLC	0.68%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Tvardi Therapeutics, Inc. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.